Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinghua Weikang capsule for maintenance treatment of reflux esophagitis
ChiCTR2400080713Phase 4Recruiting
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Feb 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of jinghuaweikang in erosive esophagitis (EE) (2 arms), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoint: Recurrence rate. Started Feb 2024; status: recruiting.
02
Drugs
jinghuaweikang
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on ChiCTR2400080713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080713.